WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today reported financial results for the first quarter of 2007. The Company reported total revenues of $23.2 million in the first quarter of 2007, compared to $11.0 million in total revenues in the first quarter of 2006, prior to the acquisition of ANTARA® (fenofibrate) capsules. During the first quarter of 2007, the Company recorded approximately $12.3 million in revenue from ANTARA. The Company also recorded approximately $11.0 million in revenues related to FACTIVE® (gemifloxacin mesylate) tablets, compared to $9.2 million in the first quarter of 2006.
